Evaluation of long-term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real-world clinical practice
Evaluation of long-term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real-world clinical practice
复制标题
在真实临床实践中使用特应性皮炎控制工具评估 dupilumab 治疗的长期疾病控制
DOI：
10.1002/cia2.12212
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Kanazawa N
中科院分区：
文献类型：
--
作者：
Kunimoto M;Imai Y*;Matsutani M;Nakatani-Kusakabe M;Nagai M;Natsuaki M;Yamanishi K;Kanazawa N
亲爱的编辑：在不同的临床试验中使用不同的指标，不可能对多个临床试验的结果进行比较。对于特应性皮炎(AD)的临床试验，核心结果集就是为了解决这个问题而开发的。1特应性皮炎控制工具(ADCT)是评估AD长期疾病控制的有效工具。2、3然而，还没有关于ADCT在现实世界临床实践中使用的研究报告。DUPILUMA是一种白介素4和白介素13的双重抑制剂，已被批准用于治疗中重度AD。最近，据报道，杜匹鲁单抗比口服环孢素有更长的药物存活期，因此，可能对AD的长期控制有用。4杜匹单抗停药后，AD患者皮疹仍可缓解。5在这项研究中，我们调查了ADCT在日常临床实践中的有效性，以评估接受双匹鲁姆治疗的AD患者的长期疾病控制。这项研究得到了兵库医学院伦理审查委员会的批准，并根据《赫尔辛基宣言》的指导方针进行。对2018年4月至2020年7月在本院接受双匹鲁单抗治疗的109例AD患者进行ADCT评估(图1A)。在这些患者中，5例未接受dupilumab治疗(dupiumab前组)，45例接受dupilumab治疗(dupiumab组)，25例未接受生物治疗
Dear Editor, As far as different indexes are used in different clinical trials, comparing the results of multiple clinical trials is impossible. For clinical trials for atopic dermatitis (AD), the core outcome set was developed to resolve this issue. 1 The Atopic Dermatitis Control Tool (ADCT) is a validated instrument for evaluating long-term disease control in AD. 2, 3 However, no studies have reported on the use of ADCT in real-world clinical practice. Dupilumab, a dual inhibitor of interleukin (IL) 4 and IL-13, is approved for use in the treatment of moderate-to-severe AD. Recently, dupilumab has been reported to show a longer drug survival than oral cyclosporine and, thus, may be useful for long-term control of AD. 4 Furthermore, the skin rash in AD can remain in remission after discontinuation of dupilumab therapy. 5 In this study, we investigated the usefulness of the ADCT in daily clinical practice for evaluating long-term disease control in patients with AD treated with dupilumab.This study was approved by the ethics review board of Hyogo College of Medicine and conducted in accordance with the guidelines of the Declaration of Helsinki. ADCT evaluation was performed in 109 patients with AD who started dupilumab therapy from April 2018 to July 2020 at our hospital (Figure 1A). Of these patients, five had not received dupilumab therapy (pre-dupilumab group), 45 were receiving dupilumab therapy (dupilumab group), 25 were in bio-free